The only PMA approved excimer laser system and disposable catheters for the treatment of coronary arterial disease. CVX-300 is also indicated for use in the treatment of peripheral arterial disease. Photoablation is the use of light to break down, vaporize and remove matter. The CVX-300 excimer laser system facilitates photoablation via a variety of Philips laser catheters to remove binding arterial plaques.
Napsauttamalla linkkiä poistut viralliselta Philips Electronics Ltd:n ("Philips") verkkosivustolta. Kaikki tällä sivustolla mahdollisesti olevat linkit kolmansien osapuolten verkkosivustoille tarjotaan vain avuksesi, eivätkä ne millään tavalla edusta minkäänlaista yhteyttä tai tukea näillä linkitetyillä verkkosivustoilla annettuihin tietoihin. Philips ei anna minkäänlaisia väitteitä tai takuita kolmansien osapuolien verkkosivustoista tai niiden sisältämistä tiedoista.
For immediate technical support, please use the phone number below.
Philips Finland
Call: 1-800-722-9377 or +358961580436
Media Gallery
Features
Indicated treatments
Indicated treatments
Removing lesions comprising atheroma, fibrosis, calcium, thrombus and neointimal hyperplasia in the coronary and peripheral vasculature, and transvenous removal of problematic pacing and defibrillator leads.
Indicated treatments
Removing lesions comprising atheroma, fibrosis, calcium, thrombus and neointimal hyperplasia in the coronary and peripheral vasculature, and transvenous removal of problematic pacing and defibrillator leads.
Indicated treatments
Removing lesions comprising atheroma, fibrosis, calcium, thrombus and neointimal hyperplasia in the coronary and peripheral vasculature, and transvenous removal of problematic pacing and defibrillator leads.
Removing lesions comprising atheroma, fibrosis, calcium, thrombus and neointimal hyperplasia in the coronary and peripheral vasculature, and transvenous removal of problematic pacing and defibrillator leads.
Peripheral procedures
Peripheral procedures
The CVX-300 can be used in the following peripheral procedures: treatment of infrainguinal stenoses and occlusions; critical limb ischemia (CLI); total occlusions crossable by guidewires.
Peripheral procedures
The CVX-300 can be used in the following peripheral procedures: treatment of infrainguinal stenoses and occlusions; critical limb ischemia (CLI); total occlusions crossable by guidewires.
Peripheral procedures
The CVX-300 can be used in the following peripheral procedures: treatment of infrainguinal stenoses and occlusions; critical limb ischemia (CLI); total occlusions crossable by guidewires.
The CVX-300 can be used in the following peripheral procedures: treatment of infrainguinal stenoses and occlusions; critical limb ischemia (CLI); total occlusions crossable by guidewires.
Coronary procedures
Coronary procedures
The CVX-300 can be used in the following coronary procedures: moderately calcified stenoses; occluded saphenous vein bypass grafts; long diffuse disease; restenosis in 316L stainless steel stents, prior to the administration of intravascular brachytherapyl; lesions that previously failed balloon angioplasty; balloon-refractory and balloon-resistant lesions; ostial lesions.
Coronary procedures
The CVX-300 can be used in the following coronary procedures: moderately calcified stenoses; occluded saphenous vein bypass grafts; long diffuse disease; restenosis in 316L stainless steel stents, prior to the administration of intravascular brachytherapyl; lesions that previously failed balloon angioplasty; balloon-refractory and balloon-resistant lesions; ostial lesions.
Coronary procedures
The CVX-300 can be used in the following coronary procedures: moderately calcified stenoses; occluded saphenous vein bypass grafts; long diffuse disease; restenosis in 316L stainless steel stents, prior to the administration of intravascular brachytherapyl; lesions that previously failed balloon angioplasty; balloon-refractory and balloon-resistant lesions; ostial lesions.
The CVX-300 can be used in the following coronary procedures: moderately calcified stenoses; occluded saphenous vein bypass grafts; long diffuse disease; restenosis in 316L stainless steel stents, prior to the administration of intravascular brachytherapyl; lesions that previously failed balloon angioplasty; balloon-refractory and balloon-resistant lesions; ostial lesions.
Lead management procedures
Lead management procedures
Laser-assisted lead removal has an established safety profile and has proven effective in multiple clinical trials.¹,² The laser sheath enables fast and predictable lead removal procedures.¹ Laser technology enables higher success rates than mechanical sheaths.¹ 30 HRS indications.³,⁴,⁵
Lead management procedures
Laser-assisted lead removal has an established safety profile and has proven effective in multiple clinical trials.¹,² The laser sheath enables fast and predictable lead removal procedures.¹ Laser technology enables higher success rates than mechanical sheaths.¹ 30 HRS indications.³,⁴,⁵
Lead management procedures
Laser-assisted lead removal has an established safety profile and has proven effective in multiple clinical trials.¹,² The laser sheath enables fast and predictable lead removal procedures.¹ Laser technology enables higher success rates than mechanical sheaths.¹ 30 HRS indications.³,⁴,⁵
Laser-assisted lead removal has an established safety profile and has proven effective in multiple clinical trials.¹,² The laser sheath enables fast and predictable lead removal procedures.¹ Laser technology enables higher success rates than mechanical sheaths.¹ 30 HRS indications.³,⁴,⁵
Removing lesions comprising atheroma, fibrosis, calcium, thrombus and neointimal hyperplasia in the coronary and peripheral vasculature, and transvenous removal of problematic pacing and defibrillator leads.
Indicated treatments
Removing lesions comprising atheroma, fibrosis, calcium, thrombus and neointimal hyperplasia in the coronary and peripheral vasculature, and transvenous removal of problematic pacing and defibrillator leads.
Indicated treatments
Removing lesions comprising atheroma, fibrosis, calcium, thrombus and neointimal hyperplasia in the coronary and peripheral vasculature, and transvenous removal of problematic pacing and defibrillator leads.
Removing lesions comprising atheroma, fibrosis, calcium, thrombus and neointimal hyperplasia in the coronary and peripheral vasculature, and transvenous removal of problematic pacing and defibrillator leads.
Peripheral procedures
Peripheral procedures
The CVX-300 can be used in the following peripheral procedures: treatment of infrainguinal stenoses and occlusions; critical limb ischemia (CLI); total occlusions crossable by guidewires.
Peripheral procedures
The CVX-300 can be used in the following peripheral procedures: treatment of infrainguinal stenoses and occlusions; critical limb ischemia (CLI); total occlusions crossable by guidewires.
Peripheral procedures
The CVX-300 can be used in the following peripheral procedures: treatment of infrainguinal stenoses and occlusions; critical limb ischemia (CLI); total occlusions crossable by guidewires.
The CVX-300 can be used in the following peripheral procedures: treatment of infrainguinal stenoses and occlusions; critical limb ischemia (CLI); total occlusions crossable by guidewires.
Coronary procedures
Coronary procedures
The CVX-300 can be used in the following coronary procedures: moderately calcified stenoses; occluded saphenous vein bypass grafts; long diffuse disease; restenosis in 316L stainless steel stents, prior to the administration of intravascular brachytherapyl; lesions that previously failed balloon angioplasty; balloon-refractory and balloon-resistant lesions; ostial lesions.
Coronary procedures
The CVX-300 can be used in the following coronary procedures: moderately calcified stenoses; occluded saphenous vein bypass grafts; long diffuse disease; restenosis in 316L stainless steel stents, prior to the administration of intravascular brachytherapyl; lesions that previously failed balloon angioplasty; balloon-refractory and balloon-resistant lesions; ostial lesions.
Coronary procedures
The CVX-300 can be used in the following coronary procedures: moderately calcified stenoses; occluded saphenous vein bypass grafts; long diffuse disease; restenosis in 316L stainless steel stents, prior to the administration of intravascular brachytherapyl; lesions that previously failed balloon angioplasty; balloon-refractory and balloon-resistant lesions; ostial lesions.
The CVX-300 can be used in the following coronary procedures: moderately calcified stenoses; occluded saphenous vein bypass grafts; long diffuse disease; restenosis in 316L stainless steel stents, prior to the administration of intravascular brachytherapyl; lesions that previously failed balloon angioplasty; balloon-refractory and balloon-resistant lesions; ostial lesions.
Lead management procedures
Lead management procedures
Laser-assisted lead removal has an established safety profile and has proven effective in multiple clinical trials.¹,² The laser sheath enables fast and predictable lead removal procedures.¹ Laser technology enables higher success rates than mechanical sheaths.¹ 30 HRS indications.³,⁴,⁵
Lead management procedures
Laser-assisted lead removal has an established safety profile and has proven effective in multiple clinical trials.¹,² The laser sheath enables fast and predictable lead removal procedures.¹ Laser technology enables higher success rates than mechanical sheaths.¹ 30 HRS indications.³,⁴,⁵
Lead management procedures
Laser-assisted lead removal has an established safety profile and has proven effective in multiple clinical trials.¹,² The laser sheath enables fast and predictable lead removal procedures.¹ Laser technology enables higher success rates than mechanical sheaths.¹ 30 HRS indications.³,⁴,⁵
Laser-assisted lead removal has an established safety profile and has proven effective in multiple clinical trials.¹,² The laser sheath enables fast and predictable lead removal procedures.¹ Laser technology enables higher success rates than mechanical sheaths.¹ 30 HRS indications.³,⁴,⁵
1. Wilkoff, Bruce L., et al. (May 1999). Pacemaker Lead Extraction with the Laser Sheath: Results of the Pacing Lead Extraction with Excimer Sheath (PLEXES) Trial. Journal of the American College of Cardiology, 33, 6.
2. Byrd, Charles, et al. (May 2002). Clinical Study of the Laser Sheath for Lead Extraction: The Total Experience in the United States. Journal of Pacing and Electrophysiology, 125, 5.
3. Wilkoff, B.L., Love, C.J., Byrd, C.L., Bongiorni, M.G., Carrillo, R.G., Crossley, G.H.,et al. (2009). Transvenous Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management.
4. Philips data on file. D014953-10. June 2017.
5. Wazni, O et. al. Lead Extraction in the Contemporary Setting: The LExICon Study: A Multicenter. Observational Retrospective Study of Consecutive Laser Lead Extractions, J Am Coll Cardiol, 55:579-586.
CVX-300 safety information
The CVX-300 is an excimer laser system approved for use in minimally invasive interventional procedures within the cardiovascular system and for the removal of problematic pacemaker and defibrillator cardiac leads.
Potential adverse events associated with procedures used to treat PAD may include: a sudden, temporary or ongoing re-closure of the treated artery; blood clot or obstruction of the artery by plaque debris; a tear, rupture or damage to the artery (or nearby vein or nerve); minor bleeding or bruising at the entry site. Other complications may occur.
Potential adverse events associated with procedures used to treat coronary artery disease may include: a tear, rupture, damage to the artery; a sudden, temporary or ongoing re-closure of the treated artery; blood clot or obstruction of the artery by plaque debris. Other complications may occur.
Potential minor adverse events associated with lead extraction procedures that may or may not require medical or surgical treatment include: a tear or damage to the blood vessels, the heart or its structures; bleeding at the surgical site; or collapsed lung.
Rare but serious adverse events that require emergency medical or surgical procedures may include: a tear or damage to the blood vessels, the heart, lungs or their structures; blood clot or obstruction of the blood vessels or lungs by debris or lead fragments. Other serious complications may include: irregular heartbeat, weakened heart muscle, infection, respiratory failure or complications associated with anesthesia, stroke or death.
This information is not intended to replace a discussion with your healthcare provider on the benefits and risks of this procedure to you.
GlideLight safety information
Indications for use: The Laser Sheath is intended for use as an adjunct to conventional lead extraction tools in patients suitable for transvenous removal of chronically implanted pacing or defibrillator leads constructed with silicone or polyurethane outer insulation.
Contraindications: Use of the Laser Sheath is contraindicated: When emergency thoracotomy with cardiopulmonary bypass cannot be performed immediately in the event of a life threatening complication;
• When fluoroscopy is not available;
• In patients in whom superior venous approach cannot be used;
• When the proximal end of the pacing lead is not accessible to the operator;
• When the lead will not fit into the inner lumen of the Laser Sheath.
• Potential Adverse Events
The following adverse events or conditions may also occur during lead extraction with the Laser Sheath, but were not observed during the clinical study (listed in alphabetical order): bacteremia, low cardiac output, migration of lead fragments, migration of vegetation, myocardial avulsion/perforation, premature ventricular contractions, pulmonary embolism, stroke, venous avulsion/perforation, ventricular tachycardia.
Risks: No clinical data has been collected using the GlideLight Laser Sheath, which operates using a maximum repetition rate of 80Hz. Therefore, complication rates are reflective of the complication rates observed with the use of the 40Hz Laser Sheath model (SLS).
Adverse events observed in clinical studies are: perioperative death, hemopericardium tamponade, hemothorax, death, any complications, pain at cut-down site, arm swelling, infection, SVC thrombosis, tricuspid regurgitation, perforation, phlebitis, and other.
ELCA important safety information
Indications: The laser catheters are intended for use either as a stand-alone modality or in conjunction with percutaneous transluminal coronary balloon angioplasty (PTCA) in patients who are acceptable candidates for coronary artery bypass graft (CABG) surgery. The following indications for use, contraindications and warnings have been established through multicenter clinical trials. The Philips CVX-300 Excimer laser system and the multi-fiber laser catheter models are safe and effective for the following indications: occluded saphenous vein bypass grafts, ostial lesions, long lesions (greater than 20mm in length), moderately calcified stenosis, total occlusions traversable by a guidewire, lesions which previously failed balloon angioplasty, restenosis in 316L stainless steel stents, prior to the administration of intravascular brachytherapy. These lesions must be traversable by a guidewire and composed of atherosclerotic plaque and/or calcified material. The lesions should be well defined by angiography.
Contraindications: Lesion is in an unprotected left main artery. Lesion is beyond acute bends or is in a location within the coronary anatomy where the catheter cannot traverse. Guidewire cannot be passed through the lesion. Lesion is located within a bifurcation. Patient is not an acceptable candidate for bypass graft surgery.
Potential adverse events: Use of the Philips CVX-300 Excimer laser system may contribute to the following complications: dissection of the arterial wall, perforation, acute reclosure, embolization, aneurysm formation, spasm, coronary artery bypass graft surgery, thrombus, myocardial infarction, arrhythmia, filling defects, death. No long term adverse effects of ELCA are known at this time.
Risks: The primary endpoint defined in the laser angioplasty of restenosis stents (LARS) randomized trial was the absence of major adverse cardiac events (MACE) at 6 months: Death; myocardial infarction; coronary artery bypass surgery. Procedural complications include: any dissection, acute thrombus, haziness, no reflow, arrhythmia, acute vessel closure, occlusion of side branch, occlusion non-target, coronary spasm, coronary embolism, coronary perforation, laser/stent damage, balloon/stent damage, and other serious.
Caution: Federal law restricts this device to sale by or on the order of a physician
Product availability is subject to country regulatory clearance. Please contact your local sales representative to check the availability in your country.
CVX-300 is distributed by LifeSystems in Australia.
Always read the label and follow the directions for use.
Philips medical devices should only be used by physicians and teams trained in interventional techniques, including training in the use of this device.
Philips reserves the right to change product specifications without prior notification.
Napsauttamalla linkkiä poistut viralliselta Philips Electronics Ltd:n ("Philips") verkkosivustolta. Kaikki tällä sivustolla mahdollisesti olevat linkit kolmansien osapuolten verkkosivustoille tarjotaan vain avuksesi, eivätkä ne millään tavalla edusta minkäänlaista yhteyttä tai tukea näillä linkitetyillä verkkosivustoilla annettuihin tietoihin. Philips ei anna minkäänlaisia väitteitä tai takuita kolmansien osapuolien verkkosivustoista tai niiden sisältämistä tiedoista.
